Reviews/COPD Pharmacotherapy/Dupilumab cuts exacerbations
Biologics · COPD-BIO-01 · v2
Two large, well-run randomised trials in people with COPD who had high blood eosinophil counts and frequent flare-ups despite maximal inhaler therapy both found that adding dupilumab led to fewer moderate-to-severe flare-ups than a placebo injection [1][2]. A combined analysis of both trials confirmed the same direction and size of effect [3], and the benefit was larger in people with the highest eosinophil counts [4] and held whether or not emphysema was present [5]. The panel treated this as strong, replicated evidence sitting directly on the claim. The main qualifications are that the clear benefit is on the combined moderate-or-severe measure rather than the most serious flare-ups counted alone [3], and that every eligible paper comes from the same two trials, the same funder, and an overlapping group of authors. The evidence therefore speaks only to the specific high-eosinophil, high-risk group studied, and only against placebo rather than other treatments.
Two independent phase 3 double-blind RCTs in COPD patients with blood eosinophils of at least 300 cells per microliter on triple therapy both reduced the annualised rate of moderate or severe exacerbations versus placebo (rate ratio 0.70 in [1]; rate ratio 0.66 in [2], both P<0.001). A pre-specified pooled analysis of the full intention-to-treat populations (N=1874) reproduced this (incidence rate ratio 0.687, 95% CI 0.595-0.793, p<0.0001) [3]. The magnitude of reduction was greater in patients with higher baseline eosinophil count (p=0.0056) and FeNO (p=0.043) [4], and the effect was stable across emphysema status (RR 0.71 and 0.69) [5] and BODE index (RR 0.656 and 0.718) [6]. The evidence maps onto each element of the claim in the population studied. The contested point: The replicated, significant result is the composite of moderate or severe exacerbations; in the pooled set the rate of severe exacerbations counted alone was not significantly reduced (0.674, 95% CI 0.438-1.037, p=0.073) [3]. The unqualified word 'exacerbations' is therefore carried mainly by the moderate component, and evidential weight rests on only two trials sharing one sponsor and an overlapping author core.
All 10 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from COPD Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The replicated significant endpoint is the moderate-OR-severe composite; the pooled severe-alone rate was not significantly reduced (0.674, 95% CI 0.438-1.037, p=0.073). The unqualified word 'exacerbations' is carried mainly by the moderate component.
Evidential independence is limited: [3][4][5][6] are all derivative analyses of BOREAS/NOTUS rather than new trials, and all six eligible papers share the same sponsor (Sanofi/Regeneron) and an overlapping author core (Bhatt, Rabe, Hanania). The genuinely independent weight is two trials, not six.
Where it remains uncertain. The reduction is significant for the moderate-or-severe composite but not for severe exacerbations alone (0.674, p=0.073) [3], and all eligible evidence derives from two trials with one sponsor and overlapping authors.
Aleatory
Severe-alone events are infrequent (annualised 0.084 vs 0.124), so the estimate is imprecise and its confidence interval crosses 1 (0.674, 95% CI 0.438-1.037) [3].
The load-bearing papers from a corpus of 10, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary RCT evidence of a significant exacerbation reduction in eosinophilic COPD.
“The annualized rate of moderate or severe exacerbations was 0.78 (95% confidence interval [CI], 0.64 to 0.93) with dupilumab and 1.10 (95% CI, 0.93 to 1.30) with placebo (rate ratio, 0.70; 95% CI, 0.58 to 0.86; P<0.001).”
Panel auditInternal validity: high · scope of inference: COPD patients with blood eosinophils ≥300/µL and elevated exacerbation risk despite triple therapy.Key limitations: single trial · restricted to ≥300 eosinophils and triple-therapy-refractory population
Independent second phase 3 RCT replicating the exacerbation reduction.
“the rate ratio as compared with placebo was 0.66 (95% CI, 0.54 to 0.82; P<0.001)”
Panel auditInternal validity: high · scope of inference: COPD patients with blood eosinophil count ≥300 cells/µL.Key limitations: primary analysis performed after a positive interim analysis · only 721 of 935 included at week 52
Pooled primary-data analysis confirming the composite exacerbation effect across both trials.
“there was no reduction in the annualised rate of severe exacerbations (annualised exacerbation rate 0·084 in the dupilumab group and 0·124 in the placebo group; 0·674, 0·438-1·037; p=0·073)”
Panel auditInternal validity: high · scope of inference: COPD current or former smokers aged 40-85 with eosinophils ≥300/µL on triple therapy; note severe exacerbations alone showed no significant reduction (rate ratio 0.674, p=0.073).Key limitations: no significant reduction in severe exacerbations alone · combines two trials as a secondary analysis
Shows the exacerbation reduction is stable across emphysema status, supporting robustness.
“Dupilumab reduced exacerbation rates vs placebo by 29 % (relative risk [RR] 0.71 [95 % CI 0.53-0.95]) and 31 % (RR 0.69 [95 % CI 0.53-0.89]) in patients with and without emphysema, respectively.”
Panel auditInternal validity: medium · scope of inference: COPD patients with eosinophils ≥300/µL in BOREAS, with and without investigator-reported emphysema.Key limitations: subgroup analysis · investigator-reported emphysema status
4 of 10 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Replicated, consistent, adequately powered phase 3 RCT evidence directly on the claim's population and outcome, tempered only by sponsor/author overlap and the non-significant severe-alone endpoint.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Sponsor-independent replication. All eligible evidence shares one funder and an overlapping author core, so confidence rests on two related trials [1][2][3]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An independently funded, investigator-initiated phase 3 or pragmatic RCT in the same eosinophilic COPD population with a moderate or severe exacerbation primary endpoint.
Open question: Does dupilumab reduce severe exacerbations when counted alone, not only within the moderate-or-severe composite? Why it is still open: The pooled severe-alone rate was not significantly reduced (0.674, 95% CI 0.438-1.037, p=0.073) [3].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19